Indivior Beheer

Beheer criteriumcontroles 3/4

De CEO Indivior is Mark Crossley, benoemd in Jun2020, heeft een ambtstermijn van 4.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 7.57M, bestaande uit 11% salaris en 89% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.077% van de aandelen van het bedrijf, ter waarde $ 1.04M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.4 jaar en 3.7 jaar.

Belangrijke informatie

Mark Crossley

Algemeen directeur

US$7.6m

Totale compensatie

Percentage CEO-salaris	11.0%
Dienstverband CEO	4.4yrs
Eigendom CEO	0.08%
Management gemiddelde ambtstermijn	4.4yrs
Gemiddelde ambtstermijn bestuur	3.7yrs

Recente managementupdates

Recent updates

Indivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025

Oct 13

Indivior: Management Takes Advantage Of Sell-Off As Board Approves Another $100m Buyback

Jul 26

Analyse CEO-vergoeding

Hoe is Mark Crossley's beloning veranderd ten opzichte van Indivior's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$3m
Jun 30 2024	n/a	n/a	-US$141m
Mar 31 2024	n/a	n/a	US$5m
Dec 31 2023	US$8m	US$834k	US$2m
Sep 30 2023	n/a	n/a	-US$235m
Jun 30 2023	n/a	n/a	-US$59m
Mar 31 2023	n/a	n/a	-US$50m
Dec 31 2022	US$11m	US$806k	-US$53m
Sep 30 2022	n/a	n/a	US$166m
Jun 30 2022	n/a	n/a	US$152m
Mar 31 2022	n/a	n/a	US$166m
Dec 31 2021	US$5m	US$775k	US$205m
Sep 30 2021	n/a	n/a	US$156m
Jun 30 2021	n/a	n/a	US$139m
Mar 31 2021	n/a	n/a	US$95m
Dec 31 2020	US$761k	US$675k	-US$148m
Sep 30 2020	n/a	n/a	-US$190m
Jun 30 2020	n/a	n/a	-US$152m
Mar 31 2020	n/a	n/a	-US$95m
Dec 31 2019	US$1m	US$528k	US$134m
Sep 30 2019	n/a	n/a	US$213m
Jun 30 2019	n/a	n/a	US$254m
Mar 31 2019	n/a	n/a	US$248m
Dec 31 2018	US$551k	US$494k	US$275m
Sep 30 2018	n/a	n/a	US$106m
Jun 30 2018	n/a	n/a	US$67m
Mar 31 2018	n/a	n/a	US$71m
Dec 31 2017	US$2m	US$413k	US$58m

Compensatie versus markt: De totale vergoeding ($USD 7.57M ) Mark } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.50M ).

Compensatie versus inkomsten: De vergoeding van Mark is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Mark Crossley

4.4yrs

Tenure

US$7,574,600

Compensatie

Mr. Mark Crossley has been Chief Executive Officer of Indivior PLC since June 29, 2020 and served as its Chief Financial and Operations Officer since July 29, 2019 until June 29, 2020. He has a wealth of f...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Mark Crossley	CEO & Executive Director	4.4yrs	US$7.57m	0.077% $ 1.0m
Ryan Preblick	CFO & Executive Director	4.4yrs	US$4.86m	0.051% $ 688.7k
Christian Heidbreder	Chief Scientific Officer	no data	geen gegevens	0.073% $ 992.7k
Jason Thompson	Vice President of Investor Relations	no data	geen gegevens	geen gegevens
Cynthia Cetani	Chief Integrity & Compliance Officer	6.1yrs	geen gegevens	0.15% $ 2.0m
Jeffrey Burris	Chief Legal Officer	2.9yrs	geen gegevens	0.00060% $ 8.1k
Richard Simkin	Chief Commercial Officer	no data	geen gegevens	0.092% $ 1.3m
Jon Fogle	Chief Human Resources Officer	less than a year	geen gegevens	0.047% $ 644.7k
Hillel West	Chief Manufacturing & Supply Officer	4.8yrs	geen gegevens	0.096% $ 1.3m
Vishal Kalia	SVP of US Treatment Access	no data	geen gegevens	0.10% $ 1.4m
Angela Colon-Mahoney	Chief Human Resources Officer	less than a year	geen gegevens	geen gegevens
Kathryn Hudson	Company Secretary	9.4yrs	geen gegevens	0.046% $ 623.8k

4.4yrs

Gemiddelde duur

Ervaren management: Het managementteam van INDV wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Mark Crossley	CEO & Executive Director	7.8yrs	US$7.57m	0.077% $ 1.0m
Ryan Preblick	CFO & Executive Director	4yrs	US$4.86m	0.051% $ 688.7k
Graham Hetherington	Independent Chairman	5yrs	US$357.97k	0.017% $ 231.3k
Juliet Thompson	Senior Independent Director	3.7yrs	US$121.62k	0.0030% $ 41.2k
Peter James Bains	Independent Non-Executive Director	5.3yrs	US$115.12k	0.0085% $ 115.3k
Barbara Ryan	Independent Non-Executive Director	2.4yrs	US$121.00k	geen gegevens
Mark Stejbach	Independent Non-Executive Director	3.7yrs	US$125.10k	0.011% $ 148.7k
David Wheadon	Independent Non-Executive Director	less than a year	geen gegevens	geen gegevens
Jerome Lande	Non-Executive Director	3.7yrs	US$103.00k	0.000050% $ 679.1
Joanna Le Couilliard	Independent Non-Executive Director	3.7yrs	US$104.92k	0.0012% $ 15.9k
Keith Humphreys	Independent Non-Executive Director	less than a year	US$17.80k	0.0019% $ 25.4k

3.7yrs

Gemiddelde duur

62.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van INDV wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).

Indivior Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Jerome Lande to Step Down from the Board of Indivior plc

Indivior PLC Announces Retirement of Graham Hetherington as Chair and from the Board

Indivior PLC Announces Board Committee Changes

Indivior PLC Appoints David E. Wheadon, M.D. as Independent Non-Executive Director, Effective from June 1, 2024

CEO & Executive Director recently sold US$1.9m worth of stock

Chief Human Resources Officer recently sold US$2.3m worth of stock

Recent updates

Indivior PLC Shares Results from a Randomized, Open-Label Sub-Study in Opioid-Dependent Participants Seeking Treatment

Jerome Lande to Step Down from the Board of Indivior plc

Oaktree Capital Sends a Letter to Indivior PLC

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Indivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025

Indivior PLC Revises Financial Guidance for the Fiscal Year 2024

Price target decreased by 18% to US$19.33

Indivior PLC's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review

Indivior PLC Announces Retirement of Graham Hetherington as Chair and from the Board

Indivior PLC Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Moderate to Severe Cannabis Use Disorder

Addex Therapeutics Ltd and Indivior PLC Selects Clinical Candidates from Gabab Positive Allosteric Modulator Research Collaboration

Pomerantz Law Firm Announces the Filing of a Class Action Against Indivior PLC and Certain Officers

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Indivior PLC (LSE:INDV) announces an Equity Buyback for 13,649,017 shares, for $100 million.

Indivior: Management Takes Advantage Of Sell-Off As Board Approves Another $100m Buyback

Indivior PLC Revises Financial Guidance for the Fiscal Year 2024

Indivior PLC(LSE:INDV) dropped from FTSE 350 (Ex Investment Companies) Index (GBP)

Indivior PLC Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (Ovee 2.7Mg) and In Naloxone (4 Mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression on Respiratory Depression

Indivior PLC Announces Dosing of First Subject with Indv-2000 in A Phase 2 Study Assessing the Safety and Efficacy of Indv-2000 in Individuals with Opioid Use Disorder

Indivior plc Reaffirms Revenue Guidance for the Year 2024

Indivior PLC Announces Board Committee Changes

Indivior plc Reconfirms Earnings Guidance for 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Indivior PLC Appoints David E. Wheadon, M.D. as Independent Non-Executive Director, Effective from June 1, 2024

Indivior PLC to Report First Half, 2024 Results on Jul 25, 2024

CEO & Executive Director recently sold US$1.9m worth of stock

Indivior PLC Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone

New minor risk - Insider selling

Chief Human Resources Officer recently sold US$2.3m worth of stock

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Indivior PLC to Report Q4, 2023 Results on Feb 22, 2024

Indivior PLC (LSE:INDV) announces an Equity Buyback for 13,631,504 shares, for $100 million.

Indivior PLC Provides Earnings Guidance for the Fiscal Year 2023

Third quarter 2023 earnings: EPS misses analyst expectations

Indivior PLC Announces Executive Changes

Indivior plc Provides Revenue Guidance for the Third Quarter and Year to Date 2023

Indivior PLC to Report Q3, 2023 Results on Nov 09, 2023

Two Seas Capital Provides Information to Shareholders of Indivior PLC

Indivior PLC Announces the Changes to the Structure and Composition of Its Board Committees Effective October 1, 2023

Indivior PLC Revises Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$0.28 (vs US$0.34 in 2Q 2022)

Indivior PLC to Report Q2, 2023 Results on Jul 27, 2023

Indivior PLC to Report First Half, 2023 Results on Jul 27, 2023

High number of new directors

Indivior PLC Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl

Indivior PLC Announces Board and Committee Changes

Indivior PLC to Report Q4, 2022 Results on Feb 16, 2023

Indivior PLC Reiterates Earnings Guidance for the Fiscal Year 2022

Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million.

Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million.

Aquestive Therapeutics Announces Positive Decision in States' Suboxone Antitrust Lawsuit on All Claims

Indivior PLC to Report Q3, 2022 Results on Oct 27, 2022

Indivior PLC, Annual General Meeting, Sep 30, 2022

Indivior PLC, Annual General Meeting, Sep 30, 2022

Indivior PLC Publishes Exploratory Study Showing That Access to Medication for Opioid Use Disorder Varies Across Organized Health Systems in the U.S

Indivior PLC Provides Revenue Guidance for the Full Year

Indivior plc Announces Executive Changes

Indivior PLC to Report Q2, 2022 Results on Jul 28, 2022

Dr. Reddy's Laboratories Limited Announces Settlement Agreement with Respect to Buprenorphine and Naloxone Sublingual Film

Indivior Names Nina DeLorenzo Chief Global Impact Officer

Indivior Announces First Patient Included in Aelis Farma's Phase 2B Study Assessing the Efficacy, Safety and Tolerability of AEF0117 in Treatment-Seeking Subjects with Moderate to Severe Cannabis Use Disorder

Indivior PLC Appoints Barbara Ryan as Independent Non-Executive Director, Effective June 1, 2022

Jerome Lande to Step Down as Member of the Audit Committee of Indivior PLC

Indivior PLC Publishes Modeling Data Showing Buprenorphine May Mitigate Fentanyl-Induced Respiratory Depression in Chronic Opioid Users

Indivior PLC, Annual General Meeting, May 05, 2022

Indivior PLC, Annual General Meeting, May 05, 2022

Indivior PLC Provides Revenue Guidance for the Year 2022

Indivior PLC to Report Fiscal Year 2021 Results on Feb 16, 2022

Indivior PLC Announces Results from Buprenorphine-Fentanyl Interaction Study in PLOS ONE